

Revision date: 15-Dec-2006 Version: 2.1 Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Tablets

Trade Name: Demulen(R)
Chemical Family: Mixture

Intended Use: Pharmaceutical product used as oral contraceptive.

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Corn Starch	9005-25-8	232-679-6	*
Microcrystalline cellulose	9004-34-6	232-674-9	*
Magnesium stearate	557-04-0	209-150-3	*
Ethinyl Estradiol	57-63-6	200-342-2	35 / 50 mcg ***
Ethynodiol Diacetate	297-76-7	206-044-9	1 mg ***

Ingredient	CAS Number	EU EINECS List	%
Calcium Acetate	62-54-4	200-540-9	*
Lactose Monohydrate	64044-51-5	Not listed	*
Povidone	9003-39-8	Not listed	*
Hydrogenated castor oil	8001-78-3	232-292-2	*
FD&C Yellow No. 6; (Sunset yellow)	2783-94-0	220-491-7	*
Dicalcium phosphate	10103-46-5	233-283-6	*
Lactose NF, anhydrous	63-42-3	200-559-2	*
FD & C Blue No. 1	3844-45-9	223-339-8	*

Additional Information: * Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: White, Blue and Pink Tablets

Signal Word: DANGER

Statement of Hazard: May be harmful if swallowed.

May cause cancer.

May damage fertility or the unborn child.

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 2 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

Additional Hazard Information:

Short Term: Active ingredient may be harmful if swallowed.

Long Term:Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss

of libido, breast tenderness, and changes in sex hormone levels have also occurred.

Occupational exposure in females has resulted in menstrual irregularities (breakthrough

bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects: Clinical use of estrogens has resulted in breast changes (enlargement, tenderness, and

secretion), along with effects on the genitourinary (changes in vaginal bleeding), and GI systems. Effects on the skin, eyes, and CNS have also been reported. The use of oral contraceptives is associated with increased risks of myocardial infarction, thromboembolism,

stroke, hepatic neoplasia, and gallbladder disease.

EU Indication of danger: Carcinogenic: Category 1

Toxic to reproduction: Category 1

Harmful

EU Hazard Symbols:



EU Risk Phrases:

R22 - Harmful if swallowed. R45 - May cause cancer. R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never

give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May include oxides of carbon.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn

out gear.

Fire / Explosion Hazards: Not applicable

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 3 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Contain the source of the spill or leak if it is safe to do so. Spills should be handled by vacuuming or wet mopping. Avoid brush sweeping and generation of airborne dust.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes, skin, and clothing.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Corn Starch

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= $5 \text{ mg/m}^3 \text{ TWA}$ = $10 \text{ mg/m}^3 \text{ TWA}$

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA Australia TWA = 10 mg/m³ TWA

Microcrystalline cellulose

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)** $= 10 \text{ mg/m}^3 \text{ TWA}$ **Australia TWA** $= 10 \text{ mg/m}^3 \text{ TWA}$

Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals

Australia TWA = 10 mg/m³ TWA

Ethinyl Estradiol

Pfizer OEL TWA-8 Hr: 40 ng/m³, Skin

Ethynodiol Diacetate

Pfizer OEL TWA-8 Hr: 0.25ug/m³

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Analytical Method: Analytical method available for ethinyl estradiol; ethynodiol. Contact Pfizer Inc for further

information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 4 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Tablets Color: White, Blue, Pink

Odor: Odorless Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Ethinyl Estradiol

Mouse Oral LD50 1737 mg/kg Rat Oral LD50 1200 mg/kg

Ethynodiol Diacetate

Rat Oral LD 50 > 5000 mg/kg

Povidone

Rat Oral LD50 100 g/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m 3

FD&C Yellow No. 6; (Sunset yellow)

Rat Oral LD50 > 10,000 mg/kg

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 5 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

Mouse Oral LD50 > 6,000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ethynodiol Diacetate

7 Year(s) Dog Oral 0.125 mg/kg/day LOAEL Reproductive system

10 Year(s) Non-human Primate Oral 5 ug/kg/day LOAEL Mammary gland, Endocrine system 10 Year(s) Non-human Primate Oral 5 μg/kg/day NOAEL Female reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ethinyl Estradiol

Embryo / Fetal Development Mouse No route specified 0.02 mg/kg/day LOEL Embryotoxicity, Not teratogenic

Ethynodiol Diacetate

Embryo / Fetal Development Mouse No route specified 1.0 mg/kg LOEL Teratogenic Embryo / Fetal Development Rat Subcutaneous Not Teratogenic 2.0 mg/kg/day NOEL Rabbit Embryo / Fetal Development Subcutaneous 0.05 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ethinyl Estradiol

Bacterial Mutagenicity (Ames) Salmonella Negative
Chromosome Aberration Human Lymphocytes Positive
Sister Chromatid Exchange Human Lymphocytes Positive
Chromosome Aberration Chinese Hamster Ovary (CHO) cells

Chromosome Aberration Chinese Hamster Ovary (CHO) cells Positive In Vivo Micronucleus Mouse Bone Marrow Positive

Ethynodiol Diacetate

In Vitro Mammalian Cell Mutagenicity Positive

Sex-Linked Recessive Lethal Test Drosophila Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ethinyl Estradiol

80 Week(s) Mouse Oral, in feed 0.07 mg/kg/day LOEL Tumors, Pituitary gland 104 Week(s) Rat No route specified 0.07 mg/kg/day LOEL Malignant tumors, Liver

105 Week(s) Rat Oral, in feed 0.053 mg/kg/day NOEL Not carcinogenic

Ethynodiol Diacetate

Not specified Male Mouse Oral Benign tumors, Liver

Not specified Male Rat Oral Benign tumors, Mammary gland

Carcinogen Status: See below

Ethinyl Estradiol

IARC: Group 1

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 6 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

NTP: Listed OSHA: Present

Ethynodiol Diacetate

IARC: Group 2B OSHA: Present

Povidone

IARC: Group 3

FD & C Blue No. 1

IARC: Group 3

FD&C Yellow No. 6; (Sunset yellow)

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Carcinogenic: Category 1

Toxic to reproduction: Category 1

Harmful

EU Risk Phrases:

R22 - Harmful if swallowed. R45 - May cause cancer. R60 - May impair fertility.

R61 - May cause harm to the unborn child.

EU Safety Phrases:

Page 7 of 8

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol

Tablets

Revision date: 15-Dec-2006 Version: 2.1

S22 - Do not breathe dust.

S36/37 - Wear suitable protective clothing and gloves.

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

DANGER

May be harmful if swallowed.

May cause cancer.

May damage fertility or the unborn child.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Calcium Acetate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-540-9

Lactose Monohydrate

Australia (AICS): Present

Corn Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-674-9

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
209-150-3

Povidone

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Hydrogenated castor oil

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-292-2

Ethinyl Estradiol

Material Name: Ethynodiol Diacetate and Ethinyl Estradiol Page 8 of 8

Tablets

Revision date: 15-Dec-2006 Version: 2.1

California Proposition 65 carcinogen, initial date 1/1/88

developmental toxicity, initial date 4/1/90 (when mixed with

Norethisterone)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

Present

Schedule 4

for Drugs and Poisons:

EU EINECS List 200-342-2

FD&C Yellow No. 6; (Sunset yellow)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
220-491-7

Dicalcium phosphate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
233-283-6

Lactose NF, anhydrous

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

200-559-2

FD & C Blue No. 1

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
223-339-8

Ethynodiol Diacetate

Australia (AICS):PresentEU EINECS List206-044-9

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard

Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet